Literature DB >> 21252144

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.

Jemma C Hopewell1, Robert Clarke, Sarah Parish, Jane Armitage, Mark Lathrop, Jorg Hager, Rory Collins.   

Abstract

BACKGROUND: Genetic studies have identified 2 single-nucleotide polymorphisms (SNPs) at the LPA locus (rs3798220 and rs10455872) that are strongly and independently related to lipoprotein(a) levels and to coronary disease risk, but their relevance for other atherothrombotic disease is uncertain. METHODS AND
RESULTS: These 2 LPA SNPs were examined together as an LPA genotype score for associations with vascular outcomes among participants in the Heart Protection Study. The LPA score was examined first in 12 236 participants with prevalent vascular disease (9277 coronary disease cases, and 1326 ischemic stroke and 2011 peripheral vascular disease cases with no history of coronary disease) and 3687 vascular disease-free controls and, subsequently, in 3251 participants who had incident major vascular events during follow-up (2106 coronary disease, 507 ischemic stroke, and 707 peripheral vascular disease events). For prevalent disease, the LPA score was strongly associated with coronary disease (odds ratio [OR] per variant allele, 1.19; 95% CI, 1.08 to 1.30) and peripheral vascular disease (OR, 1.18; 95% CI, 1.04 to 1.34) but not with ischemic stroke (OR, 1.03; 95% CI, 0.89 to 1.20). Similarly, for incident disease, the LPA score was strongly associated with coronary disease (hazard ratio [HR], 1.19; 95% CI, 1.09 to 1.30) and peripheral vascular disease (HR, 1.20; 95% CI, 1.02 to 1.40) but not with ischemic stroke (HR, 0.83; 95% CI, 0.67 to 1.03).
CONCLUSIONS: The comparable strength of associations of the LPA score with coronary disease and peripheral vascular disease but not with stroke suggest that lipoprotein(a) may have effects on atherothrombotic vascular disease that are only relevant at specific sites. Clinical Trial Registration- URL: http://isrctn.org. Unique identifier: ISRCTN48489393.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21252144     DOI: 10.1161/CIRCGENETICS.110.958371

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  15 in total

Review 1.  The genetics of diabetic complications.

Authors:  Emma Ahlqvist; Natalie R van Zuydam; Leif C Groop; Mark I McCarthy
Journal:  Nat Rev Nephrol       Date:  2015-03-31       Impact factor: 28.314

2.  Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment.

Authors:  Louise A Donnelly; Natalie R van Zuydam; Kaixin Zhou; Roger Tavendale; Fiona Carr; Anke H Maitland-van der Zee; Maarten Leusink; Anthonius de Boer; Pieter A Doevendans; Folkert W Asselbergs; Andrew D Morris; Ewan R Pearson; Olaf H Klungel; Alex S F Doney; Colin N A Palmer
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

3.  Targeted Sequencing Study to Uncover Shared Genetic Susceptibility Between Peripheral Artery Disease and Coronary Heart Disease-Brief Report.

Authors:  Maya S Safarova; Xiao Fan; Erin E Austin; Natalie van Zuydam; Jemma Hopewell; Daniel J Schaid; Iftikhar J Kullo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-06       Impact factor: 8.311

4.  LPA Gene, Ethnicity, and Cardiovascular Events.

Authors:  Sang-Rok Lee; Anand Prasad; Yun-Seok Choi; Chao Xing; Paul Clopton; Joseph L Witztum; Sotirios Tsimikas
Journal:  Circulation       Date:  2016-11-09       Impact factor: 29.690

5.  Elevated Lipoprotein (a) and Risk of Poor Functional Outcome in Chinese Patients with Ischemic Stroke and Type 2 Diabetes.

Authors:  Haoliang Wang; Jun Zhao; Yongkun Gui; Haiqing Yan; Zhixin Yan; Ping Zhang; Li Liu; Li Chang; Jianlong Zhang
Journal:  Neurotox Res       Date:  2017-12-20       Impact factor: 3.911

6.  Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels.

Authors:  Connor A Emdin; Amit V Khera; Pradeep Natarajan; Derek Klarin; Hong-Hee Won; Gina M Peloso; Nathan O Stitziel; Akihiro Nomura; Seyedeh M Zekavat; Alexander G Bick; Namrata Gupta; Rosanna Asselta; Stefano Duga; Piera Angelica Merlini; Adolfo Correa; Thorsten Kessler; James G Wilson; Matthew J Bown; Alistair S Hall; Peter S Braund; Nilesh J Samani; Heribert Schunkert; Jaume Marrugat; Roberto Elosua; Ruth McPherson; Martin Farrall; Hugh Watkins; Cristen Willer; Gonçalo R Abecasis; Janine F Felix; Ramachandran S Vasan; Eric Lander; Daniel J Rader; John Danesh; Diego Ardissino; Stacey Gabriel; Danish Saleheen; Sekar Kathiresan
Journal:  J Am Coll Cardiol       Date:  2016-12-27       Impact factor: 24.094

7.  Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study.

Authors:  Deepti Gurdasani; Barbara Sjouke; Sotirios Tsimikas; G Kees Hovingh; Robert N Luben; Nicholas W J Wainwright; Cristina Pomilla; Nicholas J Wareham; Kay-Tee Khaw; S Matthijs Boekholdt; Manjinder S Sandhu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10-11       Impact factor: 8.311

8.  The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?

Authors:  Manjinder S Sandhu; Nita G Forouhi; Zheng Ye; Philip C Haycock; Deepti Gurdasani; Cristina Pomilla; S Matthijs Boekholdt; Sotirios Tsimikas; Kay-Tee Khaw; Nicholas J Wareham
Journal:  Diabetes       Date:  2013-10-02       Impact factor: 9.461

9.  Lack of Association of LPA Gene Polymorphisms with Coronary Artery Disease in Pakistani Subjects.

Authors:  Saleem Ullah Shahid; Shabana N A; Steve Humphries
Journal:  Dis Markers       Date:  2021-06-11       Impact factor: 3.434

Review 10.  Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.

Authors:  Anping Cai; Liwen Li; Ying Zhang; Yujin Mo; Weiyi Mai; Yingling Zhou
Journal:  Dis Markers       Date:  2013-10-22       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.